Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus FOLFOX in Second-line Metastatic Colorectal Cancer
NCT01786538Phase 3Withdrawn
- Sponsor
- Asan Medical Center
- Start
- Jun 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of regorafenib in metastatic colorectal cancer (mCRC), sponsored by Asan Medical Center. Planned start Jun 2013; status: withdrawn.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01786538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01786538.